Skip to main content

ADA: Insulin Efsitora Noninferior to Glargine for Reducing HbA1c in Adults With Type 2 Diabetes

Medically reviewed by Carmen Pope, BPharm. Last updated on June 27, 2025.

via HealthDay

FRIDAY, June 27, 2025 -- Once-weekly insulin efsitora alpha (efsitora) is noninferior to once-daily insulin glargine (glargine) for reducing glycated hemoglobin (HbA1c) among adults with type 2 diabetes, according to a study published online June 25 in the New England Journal of Medicine to coincide with the annual meeting of the American Diabetes Association, held from June 20 to 23 in Chicago.

Julio Rosenstock, M.D., from Velocity Clinical Research at Medical City in Dallas, and colleagues conducted a 52-week, phase 3 trial involving adults with type 2 diabetes who had not previously received insulin. A total of 795 participants were randomly assigned to receive once-weekly efsitora, initiated at 100 U, with dose adjustments made every four weeks as needed, or once-daily insulin glargine, with doses adjusted weekly or more often to reach the same glycemic goals.

The researchers observed a decrease in mean HbA1c from baseline to week 52 from 8.20 to 7.05 percent with efsitora and from 8.28 to 7.08 percent with glargine (least-squares mean change, −1.19 and −1.16 percentage points, respectively), confirming the noninferiority of efsitora to glargine. Superiority was not achieved (P = 0.68). The rate of combined clinically significant hypoglycemia or severe hypoglycemia was lower with efsitora than glargine (0.50 versus 0.88 events per participant-year of exposure; estimated rate ratio, 0.57). The mean total weekly insulin dose was 289.1 and 332.8 U/week with efsitora and glargine, respectively, at week 52.

"Once-weekly efsitora administered in a fixed-dose regimen was noninferior to once-daily glargine in reducing glycated hemoglobin levels at 52 weeks," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Eli Lilly, which is developing efsitora and funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Diabetes Tied to Doubled Risk for Sepsis

FRIDAY, Sept. 26, 2025 -- People living with type 2 diabetes experience double the risk for incident sepsis versus matched individuals without diabetes, according to a study...

Clinical Practice Guidelines Issued for Diabetes Distress

THURSDAY, Sept. 25, 2025 -- The first clinical practice guidelines on assessment and management of diabetes distress among adults were presented at the annual meeting of the...

Oral Semaglutide Effective for Weight Loss in Overweight or Obesity

THURSDAY, Sept. 25, 2025 -- Oral semaglutide (25 mg) is effective for weight loss in adults with overweight or obesity without diabetes, according to a study published online...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.